FDA Drug recall D-0038-2024
Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx…
- FDA Drug
- Class II
- terminated
- Published 2023-10-11
On 2023-10-11 the FDA classified a Class II recall of Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx… by Zydus Pharmaceuticals Usa, citing failed Dissolution Specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0038-2024 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2023-09-21 |
| Published | 2023-10-11 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Zydus Pharmaceuticals Usa |
| Distribution | US |
Product
Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534
Reason
Failed Dissolution Specifications
Identifiers
| ndc | 68382-255-06 |
|---|---|
| ndc | 68382-255-14 |
| ndc | 68382-255-16 |
| ndc | 68382-255-01 |
| ndc | 68382-255-05 |
| ndc | 68382-255-30 |
| ndc | 68382-255-77 |
| ndc | 68382-256-14 |
| ndc | 68382-256-01 |
| ndc | 68382-256-16 |
| ndc | 68382-256-05 |
| ndc | 68382-256-30 |
| ndc | 68382-256-77 |
| ndc | 68382-256-06 |
| ndc | 68382-257-14 |
| ndc | 68382-257-01 |
| ndc | 68382-257-16 |
| ndc | 68382-257-05 |
| ndc | 68382-257-30 |
| ndc | 68382-257-77 |
| ndc | 68382-257-06 |
| code_info | Lot#: M300652 and M300651, exp. Dec 2024 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0038-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.